FDA’s Oncology Center of Excellence published a Request for Applications for projects focused on applied regulatory science research to understand factors that affect the safety and efficacy of underrepresented populations in oncology therapeutic development.
In recent months, federal policies have stripped away funding for research on sexual and gender minoritized (SGM) communities and blocked the collection of data related to gender.
